L
Lars A. Akslen
Researcher at University of Bergen
Publications - 348
Citations - 40977
Lars A. Akslen is an academic researcher from University of Bergen. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 76, co-authored 329 publications receiving 37765 citations. Previous affiliations of Lars A. Akslen include Boston Children's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Torsten O. Nielsen,Forrest D. Hsu,Kristin C. Jensen,Maggie C.U. Cheang,Gamze Karaca,Zhiyuan Hu,Tina Hernandez-Boussard,Chad A. Livasy,Dave Cowan,Lynn G. Dressler,Lars A. Akslen,Joseph Ragaz,Allen M. Gown,C. Blake Gilks,Matt van de Rijn,Charles M. Perou +15 more
TL;DR: A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors using standard available clinical tools and shows high specificity.
Journal ArticleDOI
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies
Fiona M. Blows,Kristy Driver,Marjanka K. Schmidt,Annegien Broeks,Flora E. van Leeuwen,Jelle Wesseling,Maggie C.U. Cheang,Karen A. Gelmon,Torsten O. Nielsen,Carl Blomqvist,Päivi Heikkilä,Tuomas Heikkinen,Heli Nevanlinna,Lars A. Akslen,Louis R. Bégin,William D. Foulkes,Fergus J. Couch,Xianshu Wang,Vicky Cafourek,Janet E. Olson,Laura Baglietto,Graham G. Giles,Gianluca Severi,Catriona McLean,Melissa C. Southey,Emad A. Rakha,Andrew R. Green,Ian O. Ellis,Mark E. Sherman,Jolanta Lissowska,William F. Anderson,Angela Cox,Simon S. Cross,Malcolm W.R. Reed,Elena Provenzano,Sarah-Jane Dawson,Alison M. Dunning,Manjeet K. Humphreys,Douglas F. Easton,Montserrat Garcia-Closas,Carlos Caldas,Paul D.P. Pharoah,David G. Huntsman +42 more
TL;DR: Paul Pharoah and colleagues evaluate the prognostic significance of immunohistochemical subtype classification in more than 10,000 breast cancer cases with early disease, and examines the influence of a patient's survival time on the prediction of future survival.
Journal ArticleDOI
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
William D. Foulkes,Ingunn M. Stefansson,Pierre O. Chappuis,Louis R. Bégin,John R. Goffin,Nora Wong,Michel Trudel,Lars A. Akslen +7 more
TL;DR: Germline BRCA1 mutations appear to be associated with a distinctive breast cancer phenotype, and the expression of cytokeratin 5/6 was statistically significantly associated with BRCa1-related breast cancers.
Journal ArticleDOI
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Turid Aas,Anne Lise Børresen,Stephanie Geisler,Birgitte Smith-Sørensen,Hilde Johnsen,Jan Erik Varhaug,Lars A. Akslen,Per Eystein Lønning +7 more
TL;DR: Data is presented linking specific mutations in the P53 gene to primary resistance to doxorubicin therapy and early relapse in breast cancer patients.